DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT07194317

FIDGET

CompletedPhase NA

A Feasibility Study to Determine the Most Appropriate Digital Dietary Assessment Tool in Patients With Obesity Initiating GLP-1 Receptor Agonist Treatment

Asset

GLP-1 / incretin class catch-all

Listed sites

1

Recruiting sites

—

Enrollment

64

actual

Study population

Obesity / overweight

Key I/E criterion

—

Primary endpoints

•Usability•Usability and context of use

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07194317
Org study ID347758

Timeline

Milestones

Study start2025-09-01actual
Study first posted2025-09-26actual
Primary completion2026-03-13actual
Study completion2026-04-01actual
Last update posted2026-05-29actual

Assets

Investigational agents

GLP-1 / incretin class catch-all

Study populations

Who this study enrolls

Obesity / overweight

Eligibility

Who can enroll

Minimum age18 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•Adults aged >18 years
•Living with obesity as diagnosed by healthcare professional.
•Referral to T3WMS at GSTT and currently on the service waiting list
•Eligible for GLP-1 receptor agonist (Wegovy) prescription
•Have an active MyChart account
•Have an email address
•Access to a digital device such as a smart phone, computer or tablet where you can access the internet
•Not following a meal replacement diet, for example soups / shakes
•Able to provide informed consent.
•Able to complete surveys in English.

Exclusion criteria

•Adults aged >18 years
–Living with obesity as diagnosed by healthcare professional.
–Referral to T3WMS at GSTT and currently on the service waiting list
–Eligible for GLP-1 receptor agonist (Wegovy) prescription
–Have an active MyChart account
–Have an email address
–Access to a digital device such as a smart phone, computer or tablet where you can access the internet
–Not following a meal replacement diet, for example soups / shakes
–Able to provide informed consent.
–Able to complete surveys in English.
–Not able to provide informed consent
–Not able to complete surveys in English
–Has an eating disorder
–Taking part in another research trial that involves dietary modification

Endpoints (3)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Patient-reported / QoL

3 endpoints
Primary/protocol endpoint

Usability

Time frame:Following each test period of 1 week

change from baseline, improvement

Primary/protocol endpoint

Usability and context of use

Time frame:Following each test period of 1 week]

descriptive

Secondary/protocol endpoint

Patient experience and acceptability

Time frame:Within 4 months of completion of the tool testing

descriptive

Publications (4)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.